Broadfin Capital Llc increased La Jolla Pharmaceutical Co (LJPC) stake by 605.43% reported in 2017Q3 SEC filing. Broadfin Capital Llc acquired 908,138 shares as La Jolla Pharmaceutical Co (LJPC)’s stock rose 79.23%. The Broadfin Capital Llc holds 1.06M shares with $36.80M value, up from 150,000 last quarter. La Jolla Pharmaceutical Co now has $750.06 million valuation. The stock increased 2.76% or $0.91 during the last trading session, reaching $33.87. About 452,090 shares traded. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 128.65% since February 19, 2017 and is uptrending. It has outperformed by 111.95% the S&P500.
Among 6 analysts covering Cambrex Corp (NYSE:CBM), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Cambrex Corp had 8 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by William Blair on Tuesday, January 16 with “Buy”. The firm has “Buy” rating by Craig Hallum given on Tuesday, October 31. The firm earned “Overweight” rating on Monday, November 7 by First Analysis. The stock of Cambrex Corporation (NYSE:CBM) earned “Neutral” rating by Longbow on Wednesday, February 14. The rating was maintained by First Analysis on Tuesday, January 17 with “Overweight”. Singular Research maintained it with “Buy” rating and $60 target in Thursday, February 11 report. Stephens initiated Cambrex Corporation (NYSE:CBM) rating on Tuesday, July 21. Stephens has “Overweight” rating and $55 target. See Cambrex Corporation (NYSE:CBM) latest ratings:
14/02/2018 Broker: Longbow Old Rating: Buy New Rating: Neutral Downgrade
16/01/2018 Broker: William Blair Rating: Buy Maintain
31/10/2017 Broker: Craig Hallum Rating: Buy New Target: $60.0 Maintain
The stock decreased 0.19% or $0.1 during the last trading session, reaching $52.8. About 272,877 shares traded. Cambrex Corporation (NYSE:CBM) has risen 11.15% since February 19, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.
Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.73 billion. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 17.25 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.
Investors sentiment increased to 1.58 in 2017 Q3. Its up 0.59, from 0.99 in 2017Q2. It is positive, as 18 investors sold Cambrex Corporation shares while 61 reduced holdings. 41 funds opened positions while 84 raised stakes. 31.63 million shares or 2.69% more from 30.80 million shares in 2017Q2 were reported. Fdx Advisors Inc reported 4,218 shares. Moreover, Chatham Grp Inc Inc Inc has 0.24% invested in Cambrex Corporation (NYSE:CBM). 565,658 were reported by Amer Management. Contravisory Inv Inc has 0% invested in Cambrex Corporation (NYSE:CBM). Fifth Third Bankshares holds 0% or 344 shares. Ahl Partners Llp holds 0.06% or 57,107 shares. Atria Investments Ltd Liability holds 10,103 shares. Kbc Nv accumulated 6,438 shares or 0% of the stock. Cim Inv Mangement holds 0.22% or 11,205 shares. Numeric Ltd Liability Com invested in 59,901 shares. The Pennsylvania-based Clark Cap Group has invested 0.04% in Cambrex Corporation (NYSE:CBM). Amalgamated Financial Bank owns 4,470 shares. Riverhead Cap Management Ltd Com has 3,036 shares for 0.01% of their portfolio. State Common Retirement Fund owns 244,725 shares. Comerica Bank & Trust reported 0.03% stake.
Since September 1, 2017, it had 0 insider purchases, and 2 selling transactions for $838,217 activity. $618,387 worth of Cambrex Corporation (NYSE:CBM) shares were sold by KLOSK STEVEN M.
Investors sentiment decreased to 1.61 in 2017 Q3. Its down 0.20, from 1.81 in 2017Q2. It is negative, as 10 investors sold LJPC shares while 21 reduced holdings. 25 funds opened positions while 25 raised stakes. 23.31 million shares or 1.99% less from 23.78 million shares in 2017Q2 were reported. Geode Mngmt Limited Liability Corp stated it has 149,579 shares. Ameritas Inv Partners Incorporated holds 0% or 1,535 shares in its portfolio. The Georgia-based Voya Limited Liability Corporation has invested 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Eam Invsts Ltd Llc has invested 0.22% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Goldman Sachs Group Inc owns 22,527 shares. California State Teachers Retirement Systems owns 27,968 shares. Manufacturers Life Insur The has 12,927 shares for 0% of their portfolio. California Pub Employees Retirement Systems, California-based fund reported 42,300 shares. Moreover, Bnp Paribas Arbitrage has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). New York State Common Retirement Fund has 18,300 shares. Moreover, Tower Cap Ltd Limited Liability Company (Trc) has 0.01% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Schwab Charles Investment Mngmt has 64,659 shares for 0% of their portfolio. Credit Suisse Ag has 27,425 shares. Perceptive Advsr Limited Liability accumulated 2.16M shares or 2.86% of the stock. Pictet Asset Management Ltd reported 381,432 shares.
Broadfin Capital Llc decreased Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) stake by 106,992 shares to 74,208 valued at $8.72 million in 2017Q3. It also reduced Aerie Pharmaceuticals Inc (Call) (NASDAQ:AERI) stake by 160,000 shares and now owns 150,000 shares. Veracyte Inc (NASDAQ:VCYT) was reduced too.
Since December 29, 2017, it had 1 insider purchase, and 1 sale for $5.40 million activity. Douglass Laura L. sold $323,208 worth of stock. The insider PERCEPTIVE ADVISORS LLC bought 175,000 shares worth $5.73M.
Among 8 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 5 have Buy rating, 3 Sell and 0 Hold. Therefore 63% are positive. La Jolla Pharmaceutical Company had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, January 30. The firm has “Buy” rating given on Thursday, August 31 by Jefferies. The firm has “Hold” rating given on Tuesday, August 11 by Zacks. The stock has “Buy” rating by Chardan Capital Markets on Tuesday, September 8. The rating was maintained by Jefferies with “Buy” on Monday, June 12. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) has “Buy” rating given on Friday, December 22 by Cowen & Co. The rating was initiated by J.P. Morgan on Wednesday, August 30 with “Buy”. The firm earned “Underweight” rating on Friday, December 8 by JP Morgan. Cowen & Co initiated the shares of LJPC in report on Tuesday, February 9 with “Outperform” rating. On Tuesday, May 24 the stock rating was initiated by Lake Street with “Buy”.